CORONA Remedies Limited (CORONA) has announced its unaudited financial results for the quarter and half year ended September 30, 2026, delivering the highest ever revenue with a growth of 22% year-on-year (Y-o-Y) basis. This impressive performance marks a significant milestone for the company, which continues to be one of the fastest growing companies among the top 30 Indian pharmaceutical companies.

Financial Performance

The financial performance snapshot reveals robust growth across key metrics. Revenue from operations stood at ₹441.2 crore for Q2FY27, a 22.2% increase compared to ₹361.1 crore in Q2FY26. EBITDA rose to ₹96.0 crore, up 22.3% from ₹78.5 crore in the same quarter last year. Profit After Tax (PAT) increased to ₹60.3 crore, reflecting a 15.3% growth from ₹52.3 crore in Q2FY26.

Key Business Highlights

CORONA Remedies Limited has demonstrated operational excellence and disciplined execution, leveraging all growth drivers to outperform the Indian Pharmaceutical Market (IPM). The company has now outpaced the IPM growth by 1.9 times as per MAT Sep’26. Additionally, CORONA has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad.

Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence, and investing in capabilities that will support our future growth.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.

Alembic Pharmaceuticals Limited (APLLTD) announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venetoclax Tablets, 10 mg, 50 mg, and 100 mg. This approval marks a significant milestone for Alembic, as the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Venclexta Tablets, of AbbVie Inc. Venetoclax tablets are indicated for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and, in combination with other drugs, for newly diagnosed acute myeloid leukemia (AML) in adults aged 75 or older or those with comorbidities. With this approval, Alembic may be eligible for 180 days of generic drug exclusivity. According to IQVIA, the market size for Venetoclax tablets was estimated at US $1,584 million in the United States for the twelve months ending June 2026. This approval adds to Alembic’s cumulative total of 248 ANDA approvals from the USFDA, reinforcing its position as a leader in branded generics in India.

Significance of the Approval

The USFDA approval for Venetoclax tablets is a testament to Alembic’s commitment to providing affordable and effective treatment options for various cancers. Venetoclax has shown significant efficacy in treating chronic lymphocytic leukemia and acute myeloid leukemia, offering hope to numerous patients. This approval not only expands Alembic’s generic drug portfolio but also underscores the company’s capability to deliver high-quality, cost-effective medications to the US market.

Company’s Position in the Generic Drug Market

Alembic Pharmaceuticals Limited, established in 1907, has been at the forefront of healthcare innovation. The company’s vertically integrated research and development model has enabled it to manufacture and market a wide range of generic pharmaceutical products globally. With state-of-the-art research and manufacturing facilities approved by regulatory authorities worldwide, Alembic continues to lead in the branded generics sector in India. The recent approval for Venetoclax tablets is a significant addition to its extensive list of ANDA approvals, reflecting the company’s robust pipeline and strategic growth in the generic drug market.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.

Ind-Swift Laboratories Limited (NSE: INDSWFTLAB) announced its unaudited financial results for Q2 and H1 FY27, showcasing a significant step-up in revenue, profitability, and margins. The company’s transition from an API manufacturer to a Finished Dosage Formulations (FDF) manufacturer and the scale-up of its operations have driven this performance. The company’s CDMO partnerships are now contributing better to the topline, while the shift in business mix has lifted margins.

Revenue and Profitability

Revenue grew 50.15% to ₹234.89 crore, operating EBITDA rose 5.1x to ₹42.33 crore, and operating EBITDA margin expanded by 1,279 bps to 18.02%, while PAT rose 3.5x to ₹31.03 crore, with PAT margin at 13.21%. The shift to FDF has improved our business mix and lifted margins, and the scale-up of operations is delivering operating leverage.

Operational Efficiency

Raw material expense fell to 45.15% of revenue from 49.38% a year ago, a 423 bps improvement. Growth has come from core operations, with PBT rising 3.6x to ₹40.24 crore even as non-operating other income declined. With a net-debt-free balance sheet, a focused FDF platform, and a stronger operating base, we remain committed to scaling operations further and sustaining profitable growth.

For H1 FY27, revenue rose 35.79% to ₹420.97 crore, Op. EBITDA rose 4.4x to ₹75.65 crore at a margin of 17.97%, and PAT rose 3.3x to ₹55.47 crore. The company remains optimistic about its future growth trajectory.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Ind-Swift gains 55.2% over three months and trades near its 52-week highs. Thin margins at 8.5% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -19.7% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 1.3% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 55.2% in three months. Yet revenue grows at only -19.7% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Ind-Swift Laboratories Limited.